ARGITALPENAK

  • Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, Garcia M, Aguirre C. Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation? Int. Clin. Psychopharmacol. 2018; 33(1): 56 – 58. FI: 2,284(Q3). DOI: 10.1097/YIC.0000000000000194.
  • Santos B, Gonzalez-Fraile E, Zabala A, Guillen V, Rueda JR, Ballesteros J. Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia. J. Psychopharmacol. 2018; 32(11): 1155 – 1166. FI: 4,738 (Q1). DOI: 10.1177/0269881118805496. REVIEW.
  • Lertxundi U, Hernandez R, Corcóstegui B, Ibarra O, Mentxaka G, Medrano J. Influence of an inconsistent appearance of antipsychotics on drug adherence in patients with schizophrenia. Medicine (Baltimore). 2018; 97(44): e12990. FI: 2,028(Q2). DOI: 10.1097/MD.0000000000012990.
  • Peña J, Ibarretxe-Bilbao N, Sánchez P, Uriarte JJ, Elizagarate E, Gutierrez M, et al. Mechanisms of functional improvement through cognitive rehabilitation in schizophrenia. J. Psychiatr. Res. 2018; 101: 21 – 27. FI: 4,000(Q1). DOI: 10.1016/j.jpsychires.2018.03.002.
  • Lertxundi U, Hernandez R, San Miguel S, Corcostegui B, Prieto M, Gonzalez U, et al. The burden of constipation in psychiatric hospitals. Int. J. Psychiat. Clin. 2018; 22(2): 143 – 150. FI: 1,337(Q4). DOI: 10.1080/13651501.2017.1384023.
  • Erkoreka L, Zumárraga M, Macías I, Angel Gonzalez-Torres M. The COMT Val158Met polymorphism exerts a common influence on avoidant attachment and inhibited personality, with a pattern of positive heterosis. Psychiatry Res. 2018; 262: 345 – 347. FI: 2,223(Q2). DOI: 10.1016/j.psychres.2017.07.053. LETTER.
  • Chung Y, Salvador-Carulla L, Salinas-Pérez JA, Uriarte-Uriarte JJ, Iruin-Sanz A, García-Alonso CR. Use of the self-organising map network (SOMNet) as a decision support system for regional mental health planning. Health Res. Policy Syst. 2018; 16(1): 35 – 35. FI: 2,179(Q2). DOI: 10.1186/s12961-018-0308-y.
  • Sanz-Fuentenebro J, Uriarte-Uriarte F, Bonet-Dalmau P, Molina-Rodriguez V, Lubeiro Juarez A, Bernardo Arroyo M. Variability and underutilisation of Clozapine in Spain. Schizophr. Bull. 2018; 44(1): 205 – 205. MEETING ABSTRACT.
  • Sánchez M, Castiella A, Zapata E, Zubiaurre L, Pérez-Yeboles J, Mendibil L, Iribarren A. Vitamin D levels in inpatients. Eur. Psychiat. 2018; 48: 490 – 490. MEETING ABSTRACT.
  • Trincado, S., Gonzalez, L., Uriarte, O., Ruiz de Azua, T., Peralta, D., Montero, G., Albelda, S., Irigoyen, G., Perez, D., Garnica, E., Zumarraga, M. Autoimmune Hepatitis (Immune-Mediated Liver Injury) Induced By Rosuvastatin. Gastroenterol. Hepatol. 2018; 41(5): 311 – 313. MEETING ABSTRACT.
  • Arnaiz A, Zumarraga M, Olivas O, Arrue A, Gaton M, Erkoreka L, et al. Adjunctive aripiprazole in the treatment of risperidone/paliperidone-induced hyperprolactinemia. Influence of catechol-O-methyltransferase and MAOA polymorphisms. Eur Neuropsychopharmacol. 2017;27:653-4. FI:4,239(Q1). DOI:10.1016/S0924-977X(17)31223-3. ABSTRACT
  • Basterreche N, Arrue A, Arnaiz A, Erkoreka L, Peralta D, Zumarraga M. Mania preceding pancreatic cancer. Actas Esp Psiquiatri. 2017;45:43-6. FI:1,339(Q3).
  • Bilbao A, Garcia-Perez L, Retolaza-Balsategui A, Mendezona-Pena JI, Estebanez S, de la Torre-Escalera PV, et al. Psychometric properties of the EQ-5D-5L in patients with major depression disorder. Value Health. 2017;20:758. FI:4,235(Q1). DOI:10.1016/j.jval.2017.08.2141. ABSTRACT
  • Bilbao A, Garcia-Perez M, Martin-Fernandez J, Retolaza-Balsategui A, Arrasate M, Sordo T, et al. Mapping from the Bdi-Ii to the Eq-5d-5l Questionnaire in patients with major depression disorder. Value Health. 2017;20:755-6. FI:4,235(Q1). ABSTRACT
  • Erkoreka L, Navarro B. Vulnerable narcissism is associated with severity of depressive symptoms in dysthymic patients. Psychiatry Res. 2017;257:265-9. FI:2,528(Q2). DOI:10.1016/j.psychres.2017.07.061.
  • Peñas P, Moreno MC, Uriarte JJ, Ridgway P, Iraurgi I. How is evaluated mental health recovery?. Eur Psychiatry. 2017;41:199. FI:3,123(Q2). DOI:10.1016/j.eurpsy.2017.01.2145. ABSTRACT
  • Peñas P, Uriarte JJ, Ridgway P, Moreno MC, Iraurgi I. Spanish adaptation of the recovery enhancing environments (REE) measure: Preliminary results. Eur Psychiatry. 2017;41:199. FI:3,123(Q2). DOI:10.1016/j.eurpsy.2017.01.2144. ABSTRACT
  • Ayesa-Arriola R, Rodriguez-Sanchez JM, Suero ES, Reeves LE, Tabares-Seisdedos R, Crespo-Facorro B. Diagnosis and neurocognitive profiles in first-episode non-affective psychosis patients. Eur Arch Psych Clin Neurosci. 2016;266:619-28. FI:3,569(Q2). DOI:10.1007/s00406-015-0667-0.
  • Ayesa-Arriola R, Setien-Suero E, Neergaard KD, Ferro A, Fatjo-Vilas M, Rios-Lago M, et al. Evidence for Trait Related Theory of Mind Impairment in First Episode Psychosis Patients and Its Relationship with Processing Speed: A 3 Year Follow-up Study. Front Psychol. 2016;7:592. FI:2,323(Q2). DOI:10.3389/fpsyg.2016.00592.
  • Calderón C, Balagué L, Iruin Á, Retolaza A, Belaunzaran J, Basterrechea J, et al. Primary care and mental health care collaboration in patients with depression: Evaluation of a pilot experience. Aten Primaria. 2016;48:356-65. FI:1,042(Q3). DOI:10.1016/j.aprim.2015.06.013. ABSTRACT
  • Cuellar AG, Pinto AG, Balsategui AR, Bacaicoa OA, Suarez JT, Zabala AF, et al. Deploying eHealth: A new approach to face depression. Int J Integr Care. 2016;16:UNSP S10. FI:2,230(Q2). DOI:10.5334/ijic.2557. ABSTRACT
  • Mayoral-van Son J, de la Foz VO, Martinez-Garcia O, Moreno T, Parrilla-Escobar M, Valdizan EM, et al. Clinical Outcome After Antipsychotic Treatment Discontinuation in Functionally Recovered First-Episode Nonaffective Psychosis Individuals: A 3-Year Naturalistic Follow-Up Study. J Clin Psychiatry. 2016;77:492-U111. FI:5,291(Q1). DOI:10.4088/JCP.14m09540.
  • Montero-Gonzalez G, Arnaiz A, Arrue A, Olivas O, Gordo E, Marin E, et al. Influence of genetic polymorphisms on hyperprolactinemia caused by risperidone or paliperidone and on the effect of adjunctive aripiprazole. Eur Neuropsychopharmacol. 2016;26:249-50. FI:4,239(Q1). DOI:10.1016/S0924-977X(16)31121-X. ABSTRACT
  • Peña J, Ibarretxe-Bilbao N, Sánchez P, Iriarte MB, Elizagarate E, Garay MA, et al. Combining social cognitive treatment, cognitive remediation, and functional skills training in schizophrenia: a randomized controlled trial. NPJ Schizophr. 2016;2:16037. DOI:10.1038/npjschz.2016.37.
  • Zumárraga M, Arrúe A, Basterreche N, Macías I, Catalán A, Madrazo A, et al. COMT haplotypes, catecholamine metabolites in plasma and clinical response in schizophrenic and bipolar patients. Pharmacogenomics. 2016;17:837-51. FI:2,350(Q3). DOI:10.2217/pgs-2016-0022.
  • Varela-Gomez N, Mata I, Perez-Iglesias R, Rodriguez-Sanchez JM, Ayesa R, Fatjo-Vilas M, et al. Dysbindin gene variability is associated with cognitive abnormalities in first-episode non-affective psychosis. Cogn Neuropsychiatry. 2015;20:144-156. FI:1,924(Q2). DOI: 10.1080/13546805.2014.991780.
  • Lertxundi U, Isla A, Solinis MA, Domingo-Echaburu S, Hernandez R, Peral-Aguirregoitia J, et al. Anticholinergic burden in Parkinson’s disease inpatients. Eur J Clin Pharmacol. 2015;71:1271-7. FI:2,710(Q2). DOI:10.1007/s00228-015-1919-7.
  • Lertxundi U, Domingo-Echaburu S, Hernandez R, Peral-Aguirregoitia J, Medrano J. Confusion regarding anticholinergic burden measurement. J Am Geriatr Soc. 2015;63:1054. FI:3,842(Q1). DOI: 10.1111/jgs.13411.
  • Lertxundi U, Hernandez R, Medrano J, Domingo S, Ruiz B, Garcia M, et al. Possible interaction between letrozole and long-acting injectable zuclopenthixol. Nord J Psychiat. 2015;69:79-80. FI:1,273(Q3). DOI: 10.3109/08039488.2014.915341.
  • Roiz-Santiáñez R, Ortiz-García V, Ayesa-Arriola R, Tordesillas-Gutiérrez D, Jorge R, Varela-Gómez N, et al. No progression of the alterations in the cortical thickness of individuals with schizophrenia-spectrum disorder: a three-year longitudinal magnetic resonance imaging study of first-episode patients. Psychol Med. 2015;45:2861-71. FI:5,491(Q1). DOI:10.1017/S0033291715000811.
  • Solana B, Jorquera C, Gonzalez F, Vaccari F, Nieto A, Panera C, et al. Evaluation of an outpatient intensive care Program in Public Mental Health Services in Bizkaia (Basque Country) for children with severe developmental disorders: systematization, coordination and baseline for measuring evolution. Eur Child Adolesc Psych. 2015;24:115. FI:3,339(Q1). ABSTRACT
  • Gabilondo A, Gonzalez A, Retolaza A, Fullaondo A, Prieto L, Mora J, et al. Deploying eHealth to face depression. Int J Integr Care. 2015;15. FI:1,557(Q3). ABSTRACT
  • Lubrini G, Perianez JA, Rios-Lago M, Viejo-Sobera R, Ayesa-Arriola R, Sanchez-Cubillo I, et al. Clinical Spanish Norms of the Stroop Test for Traumatic Brain Injury and Schizophrenia. Span J Psychol. 2014;17:e96. FI:0,706(Q3).
  • Ayesa-Arriola R, Rodriguez-Sanchez JM, Gomez-Ruiz E, Roiz-Santiáñez R, Reeves LL, Crespo-Facorro B. No sex differences in neuropsychological performance in first episode psychosis patients. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:149-54. FI:3,689(Q1).
  • Gutiérrez-Fernández A, Palomino A, González-Pinto A, Ugarte A, Hernanz M, Mendibil B, et al. Novel association of Neuregulin 1 gene with bipolar disorder but not with schizophrenia. Schizophr Res. 2014;159:552-3. FI:3,923(Q1).
  • Ayesa-Arriola R, Morinigo JDL, David AS, Perez-Iglesias R, Rodriguez-Sanchez JM, Crespo-Facorro B. Lack of insight 3 years after first-episode psychosis: An unchangeable illness trait determined from first presentation?. Schizophr Res. 2014;157;271-7. FI:3,923(Q1).
  • Calderón C, Mosquera I, Balagué L, Retolaza A, Bacigalupe A, Belaunzaran J, et al. Models for Primary Care and Mental Health Collaboration in the Care of People with Depression: Main Results and Methodological Challenges of a Systematic Overview. Rev Esp Salud Publica. 2014;88:113-33. FI:0,600(Q4).
  • Arteagoitia I, Zumarraga M, Davila R, Barbier L, Santamaria G, Santamaria J. Plasma variations in stress markers: Clinical trial of two anesthetics used in regional block in the extraction of impacted inferior third molars. Med Oral Patol Oral Cir Bucal. 2014;19:274-9. FI:1,171(Q3).
  • Rodríguez-Sanchez JM, Ayesa-Arriola R, Pérez-Iglesias R, Periañez JA, Martínez-García O, Gómez-Ruiz E, et al. Course of cognitive deficits in first episode of non-affective psychosis: A 3-year follow-up study. Schizophr Res. 2013;150:121-8. FI:4,426(Q1).
  • Ayesa-Arriola R, Rodríguez-Sanchez JM, Pérez-Iglesias R, Roiz-Santianez R, Martínez-García O, Sanchez-Moreno J, et al. Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. Psychopharmacology. 2013;227:615-25. FI:3,988(Q1).
  • Ayesa-Arriola R, Pérez-Iglesias R, Rodríguez-Sanchez JM, Pardo-García G, Tabares-Seisdedos R, Ayuso-Mateos JL, et al. Predictors of neurocognitive impairment at 3 years after a first episode non-affective psychosis. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;43:23-8. FI:4,025(Q1).
  • Ayesa-Arriola R, Rodriguez-Sanchez JM, Perez-Iglesias R, González-Blanch C, Pardo-García G, Tabares-Seisdedos Rl, et al. The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: A 3 year longitudinal study. Psychiatry Res. 2013;209:302-8. FI:2,682(Q2).
  • Davila W, Basterreche N, Arrue A, Zamalloa MI, Gordo E, Davila R, et al. The Influence of the Val158Met Catechol-O-Methyltransferase Polymorphism on the Personality Traits of Bipolar Patients. PLoS One. 2013; 8:e62900. FI:3,534(Q1).
  • Lertxundi U, Domingo-Echaburu S, Ruiz-Osante B, Hernández R, Peral J, Medrano J. Comments on Duran et al.’s systematic review of anticholinergic risk scales. Eur J Clin Pharmacol. 2013;69:1729. FI:2,697(Q2).
  • Paya B, Rodríguez-Sanchez JM, Otero S, Muñoz P, Castro-Fornieles J, Parellada M, et al. Premorbid impairments in early-onset psychosis: Differences between patients with schizophrenia and bipolar disorder. Schizophr Res. 2013;146:103-10. FI:4,426(Q1).
  • Torrecilla M, Fernández-Aedo I, Arrue A, Zumarraga M, Ugedo L. Role of GIRK channels on the noradrenergic transmission in vivo: an electrophysiological and neurochemical study on GIRK2 mutant mice. Int J Neuropsychopharmacol. 2013;16:1093-104. FI:5,264(Q1).